1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Lundbeck Plans To Rebuild R&D Pipeline Mean Likely Job Losses

130-160 Positions Could Go In R&D

 
• By John Davis

Lundbeck wants to rebuild its R&D pipeline of products to treat brain disorders after recent disappointments, a process that could lead to job losses among the research organization, and more emphasis on deal-making.  

Copenhagen
Copenhagen, where Lundbeck is headquartered. • Source: Shutterstock

Denmark’s Lundbeck Inc. is to “refocus and reinvigorate” its research efforts and has told its work councils that around 130-160 positions could be lost, depending on its consultation with employees, as part of planned changes to its R&D organization.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.